How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: AP Photos
US President Donald Trump has nominated White House policy aide Heidi Overton to serve as commissioner of the Food and Drug Administration (FDA), according to media reports.
Overton, who currently serves as deputy director of the White House Domestic Policy Council, is awaiting Senate approval, Bloomberg News reported.
If confirmed, she will succeed Marty Makary, who resigned in May after 13 months in the role following clashes with senior White House and health advisers and scrutiny over a series of controversial agency decisions. Kyle Diamantas has been serving as acting FDA commissioner since May.
Overton previously worked at the conservative think tank America First Policy Institute, where she ultimately oversaw its Health Policy Center.
A physician by training, Overton received her medical degree from the University of New Mexico. She completed general surgery training at Johns Hopkins and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.
She also served during the first Trump administration before joining the America First Policy Institute.
Her work also involved overseeing signature health policy efforts, including the HHS administration’s push to redesign the food pyramid, overhaul the childhood vaccine schedule and work out pricing deals with pharmaceutical companies.
Overton’s Role in Vaccine Policy
Overton appeared alongside President Trump last week when he signed an executive order calling for an overhaul of the childhood vaccine schedule. The order called for reducing the number of federally recommended shots and separating the measles, mumps and rubella (MMR) vaccine into three separate shots.
“We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out,” Overton said at the event.
She also said the order could help states identify “gold standard” recommendations and take steps to limit vaccines required for school entry.
“We are going to be working directly with states so that we’re not reliant on the court case to resolve,” Overton said, referring to ongoing litigation over pared-down vaccine recommendations. “We are doing it right away so that parents get the benefit from state laws changing.”
Criticism Over Overton’s FDA Appointment
Overton’s reported nomination has already drawn criticism from some health policy experts.
Raymond James analyst and former Trump health official Chris Meekins told Axios that Overton has degrees but “seemingly no real experience running anything.”
He also described her as a former Makary protégé who had moved further toward what he characterised as “anti-science and anti-vaccine messaging” within elements of the MAHA movement.
“Industry will view this pick as extremely troublesome and FDA career staff will continue to flee the agency,” Meekins said. “Any progress made since Makary’s departure is likely to be immediately reversed if she is confirmed.”
CDC Leadership Update
Earlier this month, the US Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention (CDC), making her the public health agency’s first permanent leader in nearly a year after months of uncertainty.
The Senate approved her nomination in a 51-44 vote on August 5.
Credit: AI
Flying thousands of metres above the ground comes with a form of exposure most passengers rarely think about: cosmic radiation. A new study has found that pilots and flight attendants have the highest and second-highest number of deaths from radiation-linked cancers among more than 500 occupations in the US.
The findings pose questions about whether repeated exposure to radiation at cruising altitude could have serious consequences for aircrew health years later.
The study, published August 17 in JAMA Internal Medicine, analysed more than 12.7 million US deaths between 2020 and 2024, covering 503 occupations. Researchers examined deaths from cancers known to have associations with ionising radiation, including breast cancer, melanoma, prostate cancer, thyroid cancer, leukemia, lymphoma and multiple myeloma.
About 6.9% of deaths among flight attendants and 6.7% among pilots were from the radiation-associated cancers examined.
That was higher than the proportion seen in other occupations, including workers with more conventional occupational radiation exposure. Nuclear technologists, for example, ranked 12th in the analysis.
The researchers also found significantly higher mortality among aircrew from several individual cancers, including breast cancer, central nervous system cancers, melanoma and prostate cancer. Pilots additionally had higher mortality from leukemia.
But this study does not prove that cosmic radiation caused these deaths. The researchers did not have individual radiation-dose measurements for each worker, and factors such as lifestyle, work schedules and other occupational exposures could also contribute.
Also read: Groundbreaking Experimental Vaccine May Prevent Pancreatic Cancer From Spreading, Early Trial Finds
At ground level, Earth's atmosphere and magnetic field provide substantial protection from cosmic radiation arriving from space. At commercial flight altitudes, there is less shielding.
Aircrew therefore receive more ionising radiation during their working lives than most other occupational groups. JAMA notes that aircrew members receive the largest mean annual effective dose of ionising radiation of any occupational group in the US, primarily because of cosmic rays encountered at commercial flight altitudes.
The amount varies depending on altitude, latitude, flight duration and solar activity. And unlike a passenger who flies occasionally, pilots and cabin crew can accumulate exposure repeatedly over years of employment.
Also read: Does Sunscreen Really Raise Skin Cancer Risk? What The 470,000-Person Study Found
This is why radiation exposure has long been considered an occupational health concern for aircrew. Previous research has also found higher rates of melanoma among pilots and cabin crew, although researchers have debated how much of that risk can be attributed to radiation versus other factors.
The study focuses on occupational exposure accumulated by people who fly regularly for their jobs. A person taking a few flights a year does not receive the same cumulative exposure as someone spending hundreds of hours in the air annually.
Harvard Medical School senior author Anupam Jena and colleagues said the findings support considering occupational radiation protections for US aircrew that are appropriate for their level of exposure.
Credit: AI
The US Department of Health and Human Services (HHS) has accused more than 200 hospitals and healthcare providers of using improper insurance billing codes to obtain coverage for gender-related medical treatments provided to minors.
The allegations are part of a new HHS report, Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of “Gender Medicine”, released this month. The report examines insurance coding, financial incentives and the provision of what the agency calls “sex-rejecting procedures” to children.
According to HHS, its review identified nearly $120 million in insurance claims since 2019 involving treatments like puberty blockers and hormone therapy.
The agency alleges that some providers used diagnostic codes unrelated to gender dysphoria, including codes for conditions like early puberty or unspecified hormonal disorders, to secure insurance reimbursement.
At the centre of the report is medical billing, rather than simply whether a particular treatment was provided. HHS alleges that some hospitals coded gender-related treatments under diagnoses that could make the procedures eligible for insurance coverage.
The department argues that this amounted to fraudulent or improper billing because the codes allegedly did not accurately describe why the treatment was being provided.
The report names several major healthcare institutions, including Mount Sinai Hospital and Boston Children's Hospital, according to Reuters.
HHS says the review covered procedures including puberty blockers, cross-sex hormones and surgeries. The report estimates that nearly $120 million in insurance charges were associated with the treatments examined since 2019. HHS argues that financial incentives helped drive the expansion of pediatric gender-related services.
The agency's report also claims that hospitals and physicians could benefit financially from establishing long-term treatment relationships with patients.
However, an allegation in an HHS report is not the same as a finding of fraud by a court or a final determination by an insurer. Individual billing and claims would need to be investigated to establish whether fraud actually occurred.
Also read: What Trump’s Childhood Vaccine Order Means: When Will It Take Effect?
The report is part of the Trump administration's broader effort to restrict gender-related medical interventions for minors.
The administration has already taken steps affecting federal funding. Earlier this month, the Centers for Medicare & Medicaid Services finalized a rule ending federal Medicaid and CHIP funding for certain gender-related procedures for children and young people.
HHS Secretary Robert F. Kennedy Jr.'s department has framed the issue as one involving both patient safety and the use of public and private healthcare funds.
Also read: Kennedy Announces Food Policy Reforms Under Trump’s MAHA Agenda: What Has Been Proposed?
Supporters of gender-affirming care argue that treatments such as puberty blockers and hormones can be medically appropriate for some adolescents with gender dysphoria and that access to such care can be important for mental health and wellbeing.
Reuters reported that supporters of the treatments dispute the HHS's characterization of the care. Boston Children's Hospital said it was reviewing the findings, while the American Hospital Association did not provide a comment to the news agency.
The allegations could lead to further scrutiny of hospitals' billing records and potential investigations into whether insurers or government health programmes were improperly charged.
© 2024 Bennett, Coleman & Company Limited